dc.creator | Dreno, Brigitte | es |
dc.creator | Ascierto, Paolo A. | es |
dc.creator | Atkinson, Victoria | es |
dc.creator | Liszkay, Gabriella | es |
dc.creator | Maio, Michele | es |
dc.creator | Mandala, Mario | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Ribas, Antoni | es |
dc.date.accessioned | 2024-03-11T16:23:52Z | |
dc.date.available | 2024-03-11T16:23:52Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Dreno, B., Ascierto, P.A., Atkinson, V., Liszkay, G., Maio, M., Mandala, M.,...,Ribas, A. (2018). Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma. British journal of cancer, 118 (6), 777-784. https://doi.org/10.1038/bjc.2017.488. | |
dc.identifier.issn | 0007-0920 | es |
dc.identifier.issn | 1532-1827 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156110 | |
dc.description.abstract | Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and
vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life
(HRQOL) from coBRIM is reported.
Methods: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
Core 30 (QLQ-C30) at baseline and X1 time point thereafter constituted the analysis population. Change from baseline X10
points was considered clinically meaningful.
Results: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains
were also comparable between arms. A transient deterioration in role function in cycle 1 day 15 (C1D15; -14.7 points) in the Pþ V arm
and improvement in insomnia in the Cþ V arm at C2D15 (-12.4 points) was observed. Among patients who experienced a X10-point
change from baseline (responders), between-group differences were greatest for insomnia (16%), social functioning (10%), fatigue (9%)
and pain (7%), all favouring C þ V. Diarrhoea, photosensitivity reaction, pyrexia, and rash did not meaningfully affect global health
status (GHS). Serous retinopathy was associated with a transient decrease in GHS at C1D15 assessment.
Conclusions: In patients with advanced/metastatic BRAFV600-mutated melanoma, treatment with C þ V maintained HRQOL
compared with P þ V, with superior efficacy. | es |
dc.format | application/pdf | es |
dc.format.extent | 8 p. | es |
dc.language.iso | eng | es |
dc.publisher | Nature publishing group | es |
dc.relation.ispartof | British journal of cancer, 118 (6), 777-784. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Vemurafenib | es |
dc.subject | Cobimetinib | es |
dc.subject | MEK inhibitor | es |
dc.subject | BRAF inhibitor | es |
dc.subject | HRQOL | es |
dc.subject | EORTC QLQ-C30 | es |
dc.subject | Metastatic melanoma | es |
dc.title | Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.nature.com/articles/bjc2017488 | es |
dc.identifier.doi | 10.1038/bjc.2017.488 | es |
dc.contributor.group | Universidad de Sevilla. CTS151: Bioquímica médica. | es |
dc.journaltitle | British journal of cancer | es |
dc.publication.volumen | 118 | es |
dc.publication.issue | 6 | es |
dc.publication.initialPage | 777 | es |
dc.publication.endPage | 784 | es |